Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotic pill may ward off winter colds, study finds

NCT ID NCT06827327

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily probiotic called LC-Plasma can prevent upper respiratory tract infections (like colds) in healthy adults aged 18-60 who often get sick. Over 600 participants took either the probiotic or a placebo pill every day for 24 weeks. Researchers tracked how many people got sick and how severe their symptoms were.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

637 people

The number who actually took part.

Started

Mar 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-60 years living in Australia * Individuals with a history of recurrent upper respiratory tract infections * Able to provide informed consent * Generally healthy * Agree to not participate in another clinical trial while enrolled in this trial * Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping/starting a new exercise regimen during entire study period * Agree not to travel internationally for over 1 month in a single trip during the intervention period (baseline to study completion). * Females of childbearing potential must a prescribed form of birth control Exclusion Criteria: * Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, neurological disorders such as multiple sclerosis. * Unstable illness e.g., changing medication/treatment. * BMI \<18.5, \>30 * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease). * Has current symptoms of an acute sickness. * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Current alcohol use (\>14 alcoholic drinks week) * Allergic to any of the ingredients in the active or placebo formula * Pregnant or lactating woman * People medically prescribed medications within the last month that would affect the immune and/or the inflammatory response excluding topical steroid use. * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month * Participants with cognitive damage * Participants with seasonal allergic rhinitis * Regular use of antihistamines * Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • RDC Clinical

    Brisbane, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.